Transfer of Proteins From Polyacrylamide Gels to Nitrocellulose Sheets
Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications
A method has been devised for the electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets. The method results in quantitative transfer of ribosomal proteins from gels containing urea. For sodium dodecyl sulfate gels, the original band pattern was obtained with no loss of resolution, but the transfer was not quantitative. The method allows detection of proteins by autoradiography and is simpler than conventional procedures.
The immobilized proteins were detectable by immunological procedures. All additional binding capacity on the nitrocellulose was blocked with excess protein; then a specific antibody was bound and, finally, a second antibody directed against the first antibody.
The second antibody was either radioactively labeled or conjugated to fluorescein or to peroxidase. The specific protein was then detected by either autoradiography, under UV light, or by the peroxidase reaction product, respectively. In the latter case, as little as 100 pg of protein was clearly detectable. It is anticipated that the procedure will be applicable to analysis of a wide variety of proteins with specific reactions or ligands.
) KIR2DL4 Recombinant Protein (Human) |
|||
| RP017041 | ABM | 100 ug | Ask for price |
 KIR2DL4 siRNA |
|||
| 20-abx921662 | Abbexa |
|
|
|
|||
 (pORF)) KIR2DL4 ORF Vector (Human) (pORF) |
|||
| ORF005681 | ABM | 1.0 ug DNA | EUR 114 |
 KIR2DL3/KIR2DL1/KIR2DL4/KIR2DS4 Antibody |
|||
| 1-CSB-PA205578 | Cusabio |
|
|
|
|||
|
Description: A polyclonal antibody against KIR2DL3/KIR2DL1/KIR2DL4/KIR2DS4. Recognizes KIR2DL3/KIR2DL1/KIR2DL4/KIR2DS4 from Human. This antibody is Unconjugated. Tested in the following application: ELISA, IHC;ELISA:1:2000-1:5000, IHC:1:50-1:200 |
|||
KIR2DL3/KIR2DL1/KIR2DL4/KIR2DS4 Antibody |
|||
| 1-CSB-PA246816 | Cusabio |
|
|
|
|||
|
Description: A polyclonal antibody against KIR2DL3/KIR2DL1/KIR2DL4/KIR2DS4. Recognizes KIR2DL3/KIR2DL1/KIR2DL4/KIR2DS4 from Human. This antibody is Unconjugated. Tested in the following application: ELISA, IHC;ELISA:1:1000-1:2000, IHC:1:50-1:100 |
|||
 KIR2DL3 / KIR2DL1 / KIR2DL4 / KIR2DS4 Antibody |
|||
| 20-abx210854 | Abbexa |
|
|
|
|||
KIR2DL3 / KIR2DL1 / KIR2DL4 / KIR2DS4 Antibody |
|||
| 20-abx339417 | Abbexa |
|
|
|
|||
 KIR2DL4 Polyclonal Antibody |
|||
| 27806-100ul | SAB | 100ul | EUR 302.4 |
KIR2DL4 Polyclonal Antibody |
|||
| 27806-50ul | SAB | 50ul | EUR 224.4 |
 KIR2DL4 Rabbit pAb |
|||
| A12836-100ul | Abclonal | 100 ul | EUR 369.6 |
KIR2DL4 Rabbit pAb |
|||
| A12836-200ul | Abclonal | 200 ul | EUR 550.8 |
KIR2DL4 Rabbit pAb |
|||
| A12836-20ul | Abclonal | 20 ul | EUR 219.6 |
KIR2DL4 Rabbit pAb |
|||
| A12836-50ul | Abclonal | 50 ul | EUR 267.6 |
 KIR2DL4 cloning plasmid |
|||
| CSB-CL857457HU-10ug | Cusabio | 10ug | EUR 279.6 |
|
|||
|
Description: A cloning plasmid for the KIR2DL4 gene. |
|||
) Recombinant Human KIR2DL4/CD158d/KIR103 (C-6His) |
|||
| C310-10ug | Novoprotein | 10ug | EUR 157.2 |
|
Description: Lyophilized from a 0.2 μm filtered solution of 20mM PB, 150mM NaCl, pH 7.4. |
|||
Recombinant Human KIR2DL4/CD158d/KIR103 (C-6His) |
|||
| C310-1mg | Novoprotein | 1mg | EUR 2739.6 |
|
Description: Lyophilized from a 0.2 μm filtered solution of 20mM PB, 150mM NaCl, pH 7.4. |
|||
Recombinant Human KIR2DL4/CD158d/KIR103 (C-6His) |
|||
| C310-500ug | Novoprotein | 500ug | EUR 1935.6 |
|
Description: Lyophilized from a 0.2 μm filtered solution of 20mM PB, 150mM NaCl, pH 7.4. |
|||
Recombinant Human KIR2DL4/CD158d/KIR103 (C-6His) |
|||
| C310-50ug | Novoprotein | 50ug | EUR 327.6 |
|
Description: Lyophilized from a 0.2 μm filtered solution of 20mM PB, 150mM NaCl, pH 7.4. |
|||
 KIR2DL4 Blocking Peptide |
|||
| 33R-9831 | Fitzgerald | 100 ug | EUR 216 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of KIR2DL4 antibody, catalog no. 70R-2365 |
|||
) KIR2DL4 sgRNA CRISPR Lentivector set (Human) |
|||
| K1150301 | ABM | 3 x 1.0 ug | EUR 406.8 |
 KIR2DL4 Recombinant Protein |
|||
| 91-290 | ProSci | 0.05 mg | EUR 556.8 |
|
Description: Killer cell immunoglobulin-like receptor 2DL4(KIR2DL4) is a Single-pass type I membrane protein and contains 2 Ig-like C2-type (immunoglobulin-like) domains.It belongs to the immunoglobulin superfamily. KIR2DL4 is expressed in all NK cells and some T cells. KIR2DL4 activates the cytotoxicity of NK cells, despite the presence of an immunoreceptor tyrosine-based inhibition motif (ITIM) in its cytoplasmic tail. The ITIM was not necessary for activation of lysis by KIR2DL4. The activation signal of KIR2DL4 was sensitive to inhibition by another ITIM-containing receptor. The activation-deficient mutant of KIR2DL4 inhibited the signal delivered by the activating receptor CD16. |
|||
 (pPM-C-HA)) KIR2DL4 Protein Vector (Human) (pPM-C-HA) |
|||
| PV022723 | ABM | 500 ng | EUR 394.8 |
 (pPB-C-His)) KIR2DL4 Protein Vector (Human) (pPB-C-His) |
|||
| PV022721 | ABM | 500 ng | EUR 394.8 |
 (pPB-N-His)) KIR2DL4 Protein Vector (Human) (pPB-N-His) |
|||
| PV022722 | ABM | 500 ng | EUR 394.8 |
 (pPM-C-His)) KIR2DL4 Protein Vector (Human) (pPM-C-His) |
|||
| PV022724 | ABM | 500 ng | EUR 394.8 |
 KIR2DL4 Polyclonal Conjugated Antibody |
|||
| C27806 | SAB | 100ul | EUR 476.4 |
 Recombinant Human KIR2DL4 Protein, His, Insect-1ug |
|||
| QP12489-1ug | EnQuireBio | 1ug | EUR 186 |
 Recombinant Human KIR2DL4 Protein, His, Insect-5ug |
|||
| QP12489-5ug | EnQuireBio | 5ug | EUR 241.2 |
 Recombinant Human KIR2DL4 Protein, His, Insect-50ug |
|||
| QP12489-50ug | EnQuireBio | 50ug | EUR 1513.2 |
 (Target 1)) KIR2DL4 sgRNA CRISPR Lentivector (Human) (Target 1) |
|||
| K1150302 | ABM | 1.0 ug DNA | EUR 184.8 |
 (Target 2)) KIR2DL4 sgRNA CRISPR Lentivector (Human) (Target 2) |
|||
| K1150303 | ABM | 1.0 ug DNA | EUR 184.8 |
 (Target 3)) KIR2DL4 sgRNA CRISPR Lentivector (Human) (Target 3) |
|||
| K1150304 | ABM | 1.0 ug DNA | EUR 184.8 |
 KIR2DL4 3'UTR GFP Stable Cell Line |
|||
| TU061796 | ABM | 1.0 ml | EUR 1825.2 |
) KIR2DL4 sgRNA CRISPR/Cas9 All-in-One Lentivector set (Human) |
|||
| K1150305 | ABM | 3 x 1.0 ug | EUR 451.2 |
 KIR2DL4 3'UTR Luciferase Stable Cell Line |
|||
| TU011796 | ABM | 1.0 ml | EUR 1825.2 |
 (Target 1)) KIR2DL4 sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 1) |
|||
| K1150306 | ABM | 1.0 ug DNA | EUR 200.4 |
 (Target 2)) KIR2DL4 sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 2) |
|||
| K1150307 | ABM | 1.0 ug DNA | EUR 200.4 |
 (Target 3)) KIR2DL4 sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 3) |
|||
| K1150308 | ABM | 1.0 ug DNA | EUR 200.4 |
 Antibody) Killer Cell Immunoglobulin-Like Receptor 2DL4 (KIR2DL4) Antibody |
|||
| abx145740-100ug | Abbexa | 100 ug | EUR 469.2 |
|
|||
 Human KIR2DL3 Antibody |
|||
| 32965-05111 | AssayPro | 150 ug | EUR 313.2 |
 KIR2DL4 Killer Cell Immunoglobulin-Like Receptor, 2 Domains Long Cytoplasmic Tail 4 Human Recombinant Protein |
|||
| PROTQ99706 | BosterBio | Regular: 5ug | EUR 380.4 |
|
Description: KIR2DL4 Human Recombinant produced in Sf9 Insect cells is a single, glycosylated polypeptide chain containing 458 amino acids (24-242 a.a.) and having a molecular mass of 51kDa (Molecular size on SDS-PAGE will appear at approximately 50-70kDa). KIR2DL4 is expressed with a 239 amino acids hIgG-His tag at C-Terminus and purified by proprietary chromatographic techniques. |
|||
 anti- KIR2DL3 antibody |
|||
| FNab04581 | FN Test | 100µg | EUR 702 |
|
|||
|
Description: Antibody raised against KIR2DL3 |
|||
 anti- KIR3DL1 antibody |
|||
| FNab04583 | FN Test | 100µg | EUR 702 |
|
|||
|
Description: Antibody raised against KIR3DL1 |
|||
 Rabbit Anti-Human KIR3DL3 polyclonal antibody |
|||
| CABT-BL004 | Creative Diagnostics | 100 ul | EUR 702 |
 Human KIR2DL2 ELISA KIT |
|||
| ELI-23746h | Lifescience Market | 96 Tests | EUR 988.8 |
 Human KIR3DL1 ELISA KIT |
|||
| ELI-23748h | Lifescience Market | 96 Tests | EUR 988.8 |
 Human KIR2DL1 ELISA KIT |
|||
| ELI-47905h | Lifescience Market | 96 Tests | EUR 988.8 |
 Human KIR3DL2 ELISA KIT |
|||
| ELI-47907h | Lifescience Market | 96 Tests | EUR 988.8 |
 Human KIR3DL3 ELISA KIT |
|||
| ELI-47908h | Lifescience Market | 96 Tests | EUR 988.8 |
) Human KIR2DL3 Antibody (Biotin Conjugate) |
|||
| 32965-05121 | AssayPro | 150 ug | EUR 442.8 |
 Human KIR2DL5B ELISA KIT |
|||
| ELI-14141h | Lifescience Market | 96 Tests | EUR 988.8 |
 Human KIR2DL5A ELISA KIT |
|||
| ELI-08129h | Lifescience Market | 96 Tests | EUR 988.8 |
 KIR2DL3 ELISA KIT|Human |
|||
| EF010535 | Lifescience Market | 96 Tests | EUR 826.8 |
 KIR3DL1 ELISA KIT|Human |
|||
| EF010537 | Lifescience Market | 96 Tests | EUR 826.8 |
 Human KIR3DL3 shRNA Plasmid |
|||
| 20-abx964456 | Abbexa |
|
|
|
|||
 Human KIR2DL1 shRNA Plasmid |
|||
| 20-abx952573 | Abbexa |
|
|
|
|||
 Human KIR2DL2 shRNA Plasmid |
|||
| 20-abx952574 | Abbexa |
|
|
|
|||
 Human KIR2DL3 shRNA Plasmid |
|||
| 20-abx952575 | Abbexa |
|
|
|
|||
 Human KIR3DL1 shRNA Plasmid |
|||
| 20-abx952580 | Abbexa |
|
|
|
|||
 Human KIR3DL2 shRNA Plasmid |
|||
| 20-abx952581 | Abbexa |
|
|
|
|||
 Human KIR2DL5A shRNA Plasmid |
|||
| 20-abx961411 | Abbexa |
|
|
|
|||
) Human KIR2DL3 AssayLite Antibody (RPE Conjugate) |
|||
| 32965-05151 | AssayPro | 150 ug | EUR 513.6 |
) Human KIR2DL3 AssayLite Antibody (APC Conjugate) |
|||
| 32965-05161 | AssayPro | 150 ug | EUR 513.6 |
 (pORF)) KIR2DL1 ORF Vector (Human) (pORF) |
|||
| ORF005679 | ABM | 1.0 ug DNA | EUR 114 |
 (pORF)) KIR2DL3 ORF Vector (Human) (pORF) |
|||
| ORF005680 | ABM | 1.0 ug DNA | EUR 114 |
 (pORF)) KIR3DL1 ORF Vector (Human) (pORF) |
|||
| ORF005682 | ABM | 1.0 ug DNA | EUR 114 |
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer
BACKGROUND
Blockade of programmed death 1 (PD-1), an inhibitory receptor expressed by T cells, can overcome immune resistance. We assessed the antitumor activity and safety of BMS-936558, an antibody that specifically blocks PD-1.
METHODS
We enrolled patients with advanced melanoma, non-small-cell lung cancer, castration-resistant prostate cancer, or renal-cell or colorectal cancer to receive anti-PD-1 antibody at a dose of 0.1 to 10.0 mg per kilogram of body weight every 2 weeks. Response was assessed after each 8-week treatment cycle. Patients received up to 12 cycles until disease progression or a complete response occurred.
RESULTS
A total of 296 patients received treatment through February 24, 2012. Grade 3 or 4 drug-related adverse events occurred in 14% of patients; there were three deaths from pulmonary toxicity. No maximum tolerated dose was defined. Adverse events consistent with immune-related causes were observed.
Among 236 patients in whom response could be evaluated, objective responses (complete or partial responses) were observed in those with non-small-cell lung cancer, melanoma, or renal-cell cancer. Cumulative response rates (all doses) were 18% among patients with non-small-cell lung cancer (14 of 76 patients), 28% among patients with melanoma (26 of 94 patients), and 27% among patients with renal-cell cancer (9 of 33 patients).
Responses were durable; 20 of 31 responses lasted 1 year or more in patients with 1 year or more of follow-up. To assess the role of intratumoral PD-1 ligand (PD-L1) expression in the modulation of the PD-1-PD-L1 pathway, immunohistochemical analysis was performed on pretreatment tumor specimens obtained from 42 patients. Of 17 patients with PD-L1-negative tumors, none had an objective response; 9 of 25 patients (36%) with PD-L1-positive tumors had an objective response (P=0.006).
CONCLUSIONS
Anti-PD-1 antibody produced objective responses in approximately one in four to one in five patients with non-small-cell lung cancer, melanoma, or renal-cell cancer; the adverse-event profile does not appear to preclude its use. Preliminary data suggest a relationship between PD-L1 expression on tumor cells and objective response. (Funded by Bristol-Myers Squibb and others; ClinicalTrials.gov number, NCT00730639.).
The 1982 revised criteria for the classification of systemic lupus erythematosus.
The 1971 preliminary criteria for the classification of systemic lupus erythematosus (SLE) were revised and updated to incorporate new immunologic knowledge and improve disease classification.
The 1982 revised criteria include fluorescence antinuclear antibody and antibody to native DNA and Sm antigen. Some criteria involving the same organ systems were aggregated into single criteria. Raynaud’s phenomenon and alopecia were not included in the 1982 revised criteria because of low sensitivity and specificity.
The new criteria were 96% sensitive and 96% specific when tested with SLE and control patient data gathered from 18 participating clinics. When compared with the 1971 criteria, the 1982 revised criteria showed gains in sensitivity and specificity.
 Rat CCL-5 ELISA Kit |
|||
| ERC0240 | Abclonal | 96Tests | EUR 625.2 |
 Goat CCL-5 ELISA Kit |
|||
| EGTC0240 | Abclonal | 96Tests | EUR 625.2 |
 Mouse CCL-5 ELISA Kit |
|||
| EMC0240 | Abclonal | 96Tests | EUR 625.2 |
 Sheep CCL-5 ELISA Kit |
|||
| ESC0240 | Abclonal | 96Tests | EUR 625.2 |
 Monkey CCL-5 ELISA Kit |
|||
| EMKC0240 | Abclonal | 96Tests | EUR 625.2 |
 Bovine CCL-5 ELISA Kit |
|||
| EBC0240 | Abclonal | 96Tests | EUR 625.2 |
 Rabbit CCL-5 ELISA Kit |
|||
| ERTC0240 | Abclonal | 96Tests | EUR 625.2 |
 Canine CCL-5 ELISA Kit |
|||
| ECC0240 | Abclonal | 96Tests | EUR 625.2 |
 Porcine CCL-5 ELISA Kit |
|||
| EPC0240 | Abclonal | 96Tests | EUR 625.2 |
 Chicken CCL-5 ELISA Kit |
|||
| ECKC0240 | Abclonal | 96Tests | EUR 625.2 |
 Anserini CCL-5 ELISA Kit |
|||
| EAC0240 | Abclonal | 96Tests | EUR 625.2 |
 Guinea Pig CCL-5 ELISA Kit |
|||
| EGC0240 | Abclonal | 96Tests | EUR 625.2 |
 Nori® Ovine CCL-2/MCP-1 ELISA Kit |
|||
| GR116154 | Genorise Scientific | 96-well | EUR 461 |
 Rabbit Anti Human Interleukin-15 Polyclonal Antibody |
|||
| CPBT-65643RH | Creative Diagnostics | 0.1 mg | EUR 1057.2 |
 Nori® Porcine CCL-2/MCP-1 ELISA Kit |
|||
| GR113217 | Genorise Scientific | 96-well | EUR 461 |
 Antibody) Human Interleukin-15 (IL-15) Antibody |
|||
| 30145-05111 | AssayPro | 150 ug | EUR 313.2 |
 Anti-Human GCDFP-15 antibody |
|||
| STJ16100371 | St John's Laboratory | 1 mL | EUR 1147.2 |
 anti-Claudin 15 |
|||
| YF-PA18066 | Abfrontier | 50 ug | EUR 435.6 |
|
Description: Mouse polyclonal to Claudin 15 |
|||
anti-Claudin 15 |
|||
| YF-PA18067 | Abfrontier | 100 ug | EUR 483.6 |
|
Description: Rabbit polyclonal to Claudin 15 |
|||
 anti-Calpain 15 |
|||
| YF-PA24745 | Abfrontier | 50 ul | EUR 400.8 |
|
Description: Mouse polyclonal to Calpain 15 |
|||
 anti-Kallikrein 15 |
|||
| YF-PA19752 | Abfrontier | 50 ul | EUR 435.6 |
|
Description: Mouse polyclonal to Kallikrein 15 |
|||
 anti-Cytokeratin 15 |
|||
| YF-PA12886 | Abfrontier | 100 ul | EUR 483.6 |
|
Description: Rabbit polyclonal to Cytokeratin 15 |
|||
anti-Cytokeratin 15 |
|||
| YF-PA12887 | Abfrontier | 100 ug | EUR 483.6 |
|
Description: Rabbit polyclonal to Cytokeratin 15 |
|||
 IL-15, Interleukin-15, human |
|||
| RC212-26 | Bio Basic | 2ug | EUR 125.26 |
|
|||
 Human CCL15/ C-C motif chemokine 15 ELISA Kit |
|||
| E0373Hu | Sunlong | 1 Kit | EUR 685.2 |
 ELISA Kit) Human CCL15(C-C motif chemokine 15) ELISA Kit |
|||
| EH0058 | FN Test | 96T | EUR 681.12 |
|
|||
|
Description: Method of detection: Double Antibody, Sandwich ELISA;Reacts with: Homo sapiens;Sensitivity: 11.719pg/ml |
|||
 Human GDF-15 Antibody |
|||
| 32574-05111 | AssayPro | 150 ug | EUR 313.2 |
 Antibody (Biotin Conjugate)) Human Interleukin-15 (IL-15) Antibody (Biotin Conjugate) |
|||
| 30145-05121 | AssayPro | 150 ug | EUR 442.8 |
 Anti-CK-15 antibody |
|||
| STJ190030 | St John's Laboratory | 200 µl | EUR 236.4 |
|
Description: Unconjugated Mouse monoclonal to CK-15 (5A1) |
|||
 Anti-IL-15 antibody |
|||
| STJ99006 | St John's Laboratory | 200 µl | EUR 236.4 |
|
Description: Rabbit polyclonal to IL-15. |
|||
 Anti-GDF-15 Antibody |
|||
| A2038-100 | Biovision | 100 µl | EUR 502.8 |
 Anti-MMP-15 Antibody |
|||
| A06396 | BosterBio | 100ul | EUR 476.4 |
|
Description: Rabbit Polyclonal MMP-15 Antibody. Validated in WB and tested in Human, Mouse. |
|||
 Anti-MMP-15 antibody |
|||
| STJ94276 | St John's Laboratory | 200 µl | EUR 236.4 |
|
Description: Rabbit polyclonal to MMP-15. |
|||
 Anti-PEA-15 antibody |
|||
| STJ95018 | St John's Laboratory | 200 µl | EUR 236.4 |
|
Description: Rabbit polyclonal to PEA-15. |
|||
Anti-PEA-15 antibody |
|||
| STJ95019 | St John's Laboratory | 200 µl | EUR 236.4 |
|
Description: Rabbit polyclonal to PEA-15. |
|||
Anti-PEA-15 antibody |
|||
| STJ95020 | St John's Laboratory | 200 µl | EUR 236.4 |
|
Description: Rabbit polyclonal to PEA-15. |
|||
 Anti-GDF-15 antibody |
|||
| STJ93253 | St John's Laboratory | 200 µl | EUR 236.4 |
|
Description: Rabbit polyclonal to GDF-15. |
|||
 Anti-BMP-15 antibody |
|||
| STJ97345 | St John's Laboratory | 200 µl | EUR 236.4 |
|
Description: Rabbit polyclonal to BMP-15. |
|||
 Anti-DHHC-15 Antibody |
|||
| A12099 | BosterBio | 100ul | EUR 476.4 |
|
Description: Rabbit Polyclonal Antibody for DHHC-15 Antibody (ZDHHC15) detection. Tested with WB in Human. |
|||
 Anti-DHHC-15 antibody |
|||
| STJ92707 | St John's Laboratory | 200 µl | EUR 236.4 |
|
Description: Rabbit polyclonal to DHHC-15. |
|||
 Anti-GCDFP-15 antibody |
|||
| STJ16100370 | St John's Laboratory | 1 mL | EUR 975.6 |
Anti-GCDFP-15 antibody |
|||
| STJ180109 | St John's Laboratory | 0.1 ml | EUR 255.6 |
 Anti-GCDFP-15 antibody |
|||
| STJ180290 | St John's Laboratory | 0.1 ml | EUR 254.4 |
 anti- Cytokeratin 15 antibody |
|||
| FNab02198 | FN Test | 100µg | EUR 606.3 |
|
|||
|
Description: Antibody raised against Cytokeratin 15 |
|||
anti- Cytokeratin 15 antibody |
|||
| FNab02199 | FN Test | 100µg | EUR 658.5 |
|
|||
|
Description: Antibody raised against Cytokeratin 15 |
|||
 anti-15 Lipoxygenase 1 |
|||
| YF-PA10168 | Abfrontier | 100 ug | EUR 483.6 |
|
Description: Rabbit polyclonal to 15 Lipoxygenase 1 |
|||
 Anti-Cytokeratin 15 Antibody |
|||
| A06791 | BosterBio | 100ul | EUR 476.4 |
|
Description: Rabbit Polyclonal Antibody for Cytokeratin 15 Antibody (KRT15) detection.tested for WB in Human, Mouse, Rat, Monkey. |
|||
 Anti-Cytokeratin 15 antibody |
|||
| PAab02198 | Lifescience Market | 100 ug | EUR 426 |
Anti-Cytokeratin 15 antibody |
|||
| STJ92628 | St John's Laboratory | 200 µl | EUR 236.4 |
|
Description: Rabbit polyclonal to Cytokeratin 15. |
|||
Anti-Cytokeratin 15 antibody |
|||
| STJ97982 | St John's Laboratory | 100 µl | EUR 280.8 |
|
Description: Mouse monoclonal to Cytokeratin 15. |
|||
) anti-p53 (Ab-15) |
|||
| LF-PA20358 | Abfrontier | 100 ul | EUR 400.8 |
|
Description: Rabbit polyclonal to p53 |
|||
) anti-CDC2 (Ab-15) |
|||
| LF-PA20070 | Abfrontier | 100 ul | EUR 400.8 |
|
Description: Rabbit polyclonal to CDC2 |
|||
) anti-HSP27 (Ab-15) |
|||
| LF-PA20219 | Abfrontier | 100 ul | EUR 400.8 |
|
Description: Rabbit polyclonal to HSP27 |
|||
) Anti-Calpain 15 (4E2) |
|||
| YF-MA15522 | Abfrontier | 100 ug | EUR 435.6 |
|
Description: Mouse monoclonal to Calpain 15 |
|||
) Anti-Calpain 15 (2H7) |
|||
| YF-MA15523 | Abfrontier | 100 ug | EUR 435.6 |
|
Description: Mouse monoclonal to Calpain 15 |
|||
 Recombinant Human Interleukin-15/IL-15 |
|||
| C016-10ug | Novoprotein | 10ug | EUR 242.4 |
|
Description: Lyophilized from a 0.2 μm filtered solution of 20mM PB, 150mM NaCl, pH 7.0. |
|||
Recombinant Human Interleukin-15/IL-15 |
|||
| C016-1mg | Novoprotein | 1mg | EUR 2203.2 |
|
Description: Lyophilized from a 0.2 μm filtered solution of 20mM PB, 150mM NaCl, pH 7.0. |
|||
Recombinant Human Interleukin-15/IL-15 |
|||
| C016-500ug | Novoprotein | 500ug | EUR 1557.6 |
|
Description: Lyophilized from a 0.2 μm filtered solution of 20mM PB, 150mM NaCl, pH 7.0. |
|||
Recombinant Human Interleukin-15/IL-15 |
|||
| C016-50ug | Novoprotein | 50ug | EUR 595.2 |
|
Description: Lyophilized from a 0.2 μm filtered solution of 20mM PB, 150mM NaCl, pH 7.0. |
|||
 anti-Protease Inhibitor 15 |
|||
| YF-PA18816 | Abfrontier | 50 ul | EUR 435.6 |
|
Description: Mouse polyclonal to Protease Inhibitor 15 |
|||
 ELISA Kit) Human C-C Motif Chemokine 15 / MIP5 (CCL15) ELISA Kit |
|||
| abx250196-96tests | Abbexa | 96 tests | EUR 904.8 |
|
|||
 ELISA Kit) Human Cancer Antigen 15-3 (CA 15-3) ELISA Kit |
|||
| PRB-5069 | Cell Biolabs | 96 assays | EUR 686.4 |
Human Cancer Antigen 15-3 (CA 15-3) ELISA Kit |
|||
| PRB-5069-5 | Cell Biolabs | 5 x 96 assays | EUR 2739.6 |
 ligand 15(CCL15) ELISA Kit) Human Chemokine (C-C motif) ligand 15(CCL15) ELISA Kit |
|||
| YLA3875HU-48T | Shanghai YL Biotech | 48T | EUR 435 |
Human Chemokine (C-C motif) ligand 15(CCL15) ELISA Kit |
|||
| YLA3875HU-96T | Shanghai YL Biotech | 96T | EUR 562.5 |
 Rabbit Anti Human Ccl17 Polyclonal Antibody |
|||
| CPBT-65034RH | Creative Diagnostics | 0.1 mg | EUR 1057.2 |
 Rabbit Anti Human Ccl25 Polyclonal Antibody |
|||
| CPBT-65036RH | Creative Diagnostics | 0.1 mg | EUR 1057.2 |